Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.

Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, Nguyen-Viet TA, Bowers P, Sidorenko J, Karlsson Linnér R, Fontana MA, Kundu T, Lee C, Li H, Li R, Royer R, Timshel PN, Walters RK, Willoughby EA, Yengo L; 23andMe Research Team; COGENT (Cognitive Genomics Consortium); Social Science Genetic Association Consortium, Alver M, Bao Y, Clark DW, Day FR, Furlotte NA, Joshi PK, Kemper KE, Kleinman A, Langenberg C, Mägi R, Trampush JW, Verma SS, Wu Y, Lam M, Zhao JH, Zheng Z, Boardman JD, Campbell H, Freese J, Harris KM, Hayward C, Herd P, Kumari M, Lencz T, Luan J, Malhotra AK, Metspalu A, Milani L, Ong KK, Perry JRB, Porteous DJ, Ritchie MD, Smart MC, Smith BH, Tung JY, Wareham NJ, Wilson JF, Beauchamp JP, Conley DC, Esko T, Lehrer SF, Magnusson PKE, Oskarsson S, Pers TH, Robinson MR, Thom K, Watson C, Chabris CF, Meyer MN, Laibson DI, Yang J, Johannesson M, Koellinger PD, Turley P, Visscher PM, Benjamin DJ, Cesarini D.

Nat Genet. 2018 Jul 23;50(8):1112-1121. doi: 10.1038/s41588-018-0147-3.

2.

Activation of anti-oxidant Nrf2 signaling by enone analogues of curcumin.

Deck LM, Hunsaker LA, Vander Jagt TA, Whalen LJ, Royer RE, Vander Jagt DL.

Eur J Med Chem. 2018 Jan 1;143:854-865. doi: 10.1016/j.ejmech.2017.11.048. Epub 2017 Nov 21.

PMID:
29223100
3.

Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patients on Anticoagulation or Antiplatelet Therapy.

LaVallee J, Royer R, Smith G.

PM R. 2017 Dec;9(12):1217-1224. doi: 10.1016/j.pmrj.2017.06.002. Epub 2017 Jun 16.

PMID:
28629806
4.

A high frequency of PALB2 mutations in Jamaican patients with breast cancer.

Lerner-Ellis J, Donenberg T, Ahmed H, George S, Wharfe G, Chin S, Lowe D, Royer R, Zhang S, Narod S, Hurley J, Akbari MR.

Breast Cancer Res Treat. 2017 Apr;162(3):591-596. doi: 10.1007/s10549-017-4148-1. Epub 2017 Feb 13.

PMID:
28194609
5.

Activation of anti-oxidant Nrf2 signaling by substituted trans stilbenes.

Deck LM, Whalen LJ, Hunsaker LA, Royer RE, Vander Jagt DL.

Bioorg Med Chem. 2017 Feb 15;25(4):1423-1430. doi: 10.1016/j.bmc.2017.01.005. Epub 2017 Jan 6.

PMID:
28126440
6.

Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.

Moran O, Nikitina D, Royer R, Poll A, Metcalfe K, Narod SA, Akbari MR, Kotsopoulos J.

Breast Cancer Res Treat. 2017 Jan;161(1):135-142. doi: 10.1007/s10549-016-4038-y. Epub 2016 Oct 31.

PMID:
27798748
7.

A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.

Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, Akbari MR, Ali J, Hurley J.

Breast Cancer Res Treat. 2016 Aug;159(1):131-8. doi: 10.1007/s10549-016-3870-4. Epub 2016 Jul 28.

PMID:
27469594
8.

Profiling Fanconi Anemia Gene Mutations among Iranian Patients.

Esmail Nia G, Fadaee M, Royer R, Najmabadi H, Akbari MR.

Arch Iran Med. 2016 Apr;19(4):236-40. doi: 0161904/AIM.003.

9.

Managing Chronic Conditions In Older Adults.

Royer RA.

Provider. 2015 Dec;41(12):39, 41, 43. No abstract available.

PMID:
26749986
10.

Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.

Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Francis W, Halliday D, Royer R, Zhang S, Li S, Thompson I, Donenberg T, Hurley J, Akbari MR, Narod SA.

Clin Genet. 2016 Mar;89(3):328-31. doi: 10.1111/cge.12602. Epub 2015 May 31.

PMID:
25920394
11.

Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry.

Snyder C, Metcalfe K, Sopik V, Royer R, Zhang S, Narod SA, Akbari MR, Lynch HT.

Breast Cancer Res Treat. 2015 Apr;150(3):637-41. doi: 10.1007/s10549-015-3347-x. Epub 2015 Mar 21.

PMID:
25794774
12.

The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.

Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, Alvarez-Gómez RM, Herzog J, Castillo D, Royer R, Akbari M, Lara-Medina F, Herrera LA, Mohar A, Narod SA.

Breast Cancer Res Treat. 2015 Apr;150(2):389-94. doi: 10.1007/s10549-015-3312-8. Epub 2015 Feb 26.

13.

Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer.

Torres-Mejía G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martínez-Matsushita L, Angeles-Llerenas A, Ortega-Olvera C, Ziv E, Lazcano-Ponce E, Phelan CM, Narod SA.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):498-505. doi: 10.1158/1055-9965.EPI-13-0980. Epub 2014 Nov 4.

14.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.

Abugattas J, Llacuachaqui M, Allende YS, Velásquez AA, Velarde R, Cotrina J, Garcés M, León M, Calderón G, de la Cruz M, Mora P, Royer R, Herzog J, Weitzel JN, Narod SA.

Clin Genet. 2015 Oct;88(4):371-5. doi: 10.1111/cge.12505. Epub 2014 Oct 28.

15.

Long-term potential of in situ chemical reduction for treatment of polychlorinated biphenyls in soils.

Olson MR, Blotevogel J, Borch T, Petersen MA, Royer RA, Sale TC.

Chemosphere. 2014 Nov;114:144-9. doi: 10.1016/j.chemosphere.2014.03.109. Epub 2014 May 14.

PMID:
25113195
16.

Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.

Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA.

Clin Genet. 2015 Aug;88(2):182-6. doi: 10.1111/cge.12468. Epub 2014 Sep 6.

PMID:
25060751
17.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia.

Hernández JE, Llacuachaqui M, Palacio GV, Figueroa JD, Madrid J, Lema M, Royer R, Li S, Larson G, Weitzel JN, Narod SA.

Hered Cancer Clin Pract. 2014 Apr 17;12(1):11. doi: 10.1186/1897-4287-12-11. eCollection 2014.

18.

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing.

Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA.

Br J Cancer. 2013 Aug 6;109(3):777-9. doi: 10.1038/bjc.2013.309. Epub 2013 Jun 18.

19.

Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.

Ghadirian P, Robidoux A, Nassif E, Martin G, Potvin C, Patocskai E, Younan R, Larouche N, Venne A, Zhang S, Royer R, Narod SA.

Clin Genet. 2014 Jan;85(1):31-5. doi: 10.1111/cge.12174. Epub 2013 Jun 5.

PMID:
23621881
20.

Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics.

Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST.

Breast J. 2013 Mar-Apr;19(2):189-92. doi: 10.1111/tbj.12083. Epub 2013 Jan 16.

PMID:
23320992
21.

The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer.

Akbari MR, Kluźniak W, Rodin R, Li S, Wokołorczyk D, Royer R, Kashyap A, Menkiszak J, Lubinski J, Narod SA, Cybulski C.

Breast Cancer Res Treat. 2012 Dec;136(3):907-9. doi: 10.1007/s10549-012-2295-y. Epub 2012 Oct 26.

22.

The R337H mutation in TP53 and breast cancer in Brazil.

Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A, Pitombo MB, F Leal PR, Royer R, Zhang P, Narod SA.

Hered Cancer Clin Pract. 2012 Mar 28;10(1):3. doi: 10.1186/1897-4287-10-3.

23.

A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization.

Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Jagt DL.

PLoS One. 2012;7(3):e31869. doi: 10.1371/journal.pone.0031869. Epub 2012 Mar 19.

24.

Synthesis of benzyl substituted naphthalenes from benzylidene tetralones.

Deck LM, Mgani Q, Martinez A, Martinic A, Whalen LJ, Vander Jagt DL, Royer RE.

Tetrahedron Lett. 2012 Jan 25;53(4):373-376.

25.

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece.

Koumpis C, Dimitrakakis C, Antsaklis A, Royer R, Zhang S, Narod SA, Kotsopoulos J.

Hered Cancer Clin Pract. 2011 Nov 15;9:10. doi: 10.1186/1897-4287-9-10.

26.

BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia.

Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, Narod SA.

Gynecol Oncol. 2012 Feb;124(2):236-43. doi: 10.1016/j.ygyno.2011.10.027. Epub 2011 Oct 29.

PMID:
22044689
27.

Clinical impact of unclassified variants of the BRCA1 and BRCA2 genes.

Akbari MR, Zhang S, Fan I, Royer R, Li S, Risch H, McLaughlin J, Rosen B, Sun P, Narod SA.

J Med Genet. 2011 Nov;48(11):783-6. doi: 10.1136/jmedgenet-2011-100305. Epub 2011 Oct 1.

PMID:
21965345
28.

The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.

Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, Foulkes WD, Tischkowitz M, Narod SA, Provencher D, Tonin PN.

Breast Cancer Res Treat. 2012 Jan;131(1):333-40. doi: 10.1007/s10549-011-1796-4. Epub 2011 Sep 27. Erratum in: Breast Cancer Res Treat. 2012 Jan;131(1):341.

PMID:
21947752
29.

BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.

Gutiérrez Espeleta GA, Llacuachaqui M, García-Jiménez L, Aguilar Herrera M, Loáiciga Vega K, Ortiz A, Royer R, Li S, Narod SA.

Clin Genet. 2012 Nov;82(5):484-8. doi: 10.1111/j.1399-0004.2011.01774.x. Epub 2011 Oct 5.

PMID:
21895635
30.

Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor.

Paquette B, Therriault H, Desmarais G, Wagner R, Royer R, Bujold R.

Br J Cancer. 2011 Aug 9;105(4):534-41. doi: 10.1038/bjc.2011.260. Epub 2011 Jul 26.

31.

Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.

Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA.

Gynecol Oncol. 2011 May 1;121(2):353-7. doi: 10.1016/j.ygyno.2011.01.020. Epub 2011 Feb 15.

PMID:
21324516
32.

Family history, BRCA mutations and breast cancer in Vietnamese women.

Ginsburg OM, Dinh NV, To TV, Quang LH, Linh ND, Duong BT, Royer R, Llacuachaqui M, Tulman A, Vichodez G, Li S, Love RR, Narod SA.

Clin Genet. 2011 Jul;80(1):89-92. doi: 10.1111/j.1399-0004.2010.01545.x. Epub 2010 Oct 18.

PMID:
20950396
33.

Synthesis of Hemigossypol and its Derivatives.

Wei J, Vander Jagt DL, Royer RE, Deck LM.

Tetrahedron Lett. 2010 Oct 3;51(44):5757-5760. Epub 2010 Aug 30.

34.

A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas.

Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Royer R, Narod SA, Hurley J.

Breast Cancer Res Treat. 2011 Jan;125(2):591-6. doi: 10.1007/s10549-010-1156-9. Epub 2010 Sep 14.

PMID:
20838878
35.

International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation.

Peixoto A, Santos C, Pinheiro M, Pinto P, Soares MJ, Rocha P, Gusmão L, Amorim A, van der Hout A, Gerdes AM, Thomassen M, Kruse TA, Cruger D, Sunde L, Bignon YJ, Uhrhammer N, Cornil L, Rouleau E, Lidereau R, Yannoukakos D, Pertesi M, Narod S, Royer R, Costa MM, Lazaro C, Feliubadaló L, Graña B, Blanco I, de la Hoya M, Caldés T, Maillet P, Benais-Pont G, Pardo B, Laitman Y, Friedman E, Velasco EA, Durán M, Miramar MD, Valle AR, Calvo MT, Vega A, Blanco A, Diez O, Gutiérrez-Enríquez S, Balmaña J, Ramon y Cajal T, Alonso C, Baiget M, Foulkes W, Tischkowitz M, Kyle R, Sabbaghian N, Ashton-Prolla P, Ewald IP, Rajkumar T, Mota-Vieira L, Giannini G, Gulino A, Achatz MI, Carraro DM, de Paillerets BB, Remenieras A, Benson C, Casadei S, King MC, Teugels E, Teixeira MR.

Breast Cancer Res Treat. 2011 Jun;127(3):671-9. doi: 10.1007/s10549-010-1036-3. Epub 2010 Jul 22.

36.

Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube.

Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, Royer R, McLaughlin J, Karlan B, Narod SA.

Gynecol Oncol. 2010 Sep;118(3):299-302. doi: 10.1016/j.ygyno.2010.05.011. Epub 2010 Jun 8.

PMID:
20570322
37.

Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs.

Orlando RA, Gonzales AM, Hunsaker LA, Franco CR, Royer RE, Vander Jagt DL, Vander Jagt DJ.

J Med Food. 2010 Aug;13(4):888-95. doi: 10.1089/jmf.2009.1128.

38.

Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML.

Blood. 2010 Jun 3;115(22):4464-71. doi: 10.1182/blood-2009-10-247973. Epub 2010 Mar 22.

39.

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.

Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42. doi: 10.1073/pnas.0914433107. Epub 2010 Jan 19.

40.

Decade of patient safety.

Miller R, Kuhn HB, Swarens CC, Royer RA.

Mo Med. 2009 Nov-Dec;106(6):413. No abstract available.

PMID:
20063511
41.

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA.

J Clin Oncol. 2010 Jan 20;28(3):387-91. doi: 10.1200/JCO.2009.25.0712. Epub 2009 Dec 14.

PMID:
20008623
42.

Not just for show. Missouri's safety efforts preceded IOM report, continue quietly today.

Miller R, Kuhn H, Swarens CC, Royer R.

Mod Healthc. 2009 Nov 23;39(47):24. No abstract available.

PMID:
19972683
43.

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.

Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD.

Clin Genet. 2009 Nov;76(5):421-6. doi: 10.1111/j.1399-0004.2009.01277.x.

PMID:
19863560
44.

The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.

Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA.

Fam Cancer. 2009;8(4):563-7. doi: 10.1007/s10689-009-9287-z.

PMID:
19714488
45.

Polymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancer.

Bentov Y, Brown TJ, Akbari MR, Royer R, Risch H, Rosen B, McLaughlin J, Sun P, Zhang S, Narod SA, Casper RF.

PLoS One. 2009 Jun 15;4(6):e5918. doi: 10.1371/journal.pone.0005918.

46.

[Bortezomib-induced eruption: Sweet syndrome? Two case reports].

Thuillier D, Lenglet A, Chaby G, Royer R, Vaida I, Viseux V, Dadban A, Billet A, Christophe O, Chatelain D, Marolleau JP, Lok C, Damaj G.

Ann Dermatol Venereol. 2009 May;136(5):427-30. doi: 10.1016/j.annder.2008.10.039. Epub 2009 Feb 27. French.

PMID:
19442799
47.

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.

Young SR, Pilarski RT, Donenberg T, Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B, Desai D, Zandvakili I, Royer R, Li S, Narod SA.

BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.

48.

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.

Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, Scott J, Royer R, Sun P, Narod SA.

Br J Cancer. 2009 Jan 27;100(2):421-5. doi: 10.1038/sj.bjc.6604830. Epub 2008 Dec 16.

49.

Isocoumarin-based inhibitors of pancreatic cholesterol esterase.

Heynekamp JJ, Hunsaker LA, Vander Jagt TA, Royer RE, Deck LM, Vander Jagt DL.

Bioorg Med Chem. 2008 May 1;16(9):5285-94. doi: 10.1016/j.bmc.2008.03.016. Epub 2008 Mar 6.

50.

Germline RAP80 mutations and susceptibility to breast cancer.

Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R, Zandvakili I, Lynch H, Narod SA.

Breast Cancer Res Treat. 2009 Jan;113(2):377-81. doi: 10.1007/s10549-008-9938-z. Epub 2008 Feb 28.

PMID:
18306035

Supplemental Content

Support Center